Department of Ophthalmology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Department of Pathology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Department of Ophthalmology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Surv Ophthalmol. 2020 Nov-Dec;65(6):691-707. doi: 10.1016/j.survophthal.2020.04.001. Epub 2020 Apr 15.
Malignant tumors of epithelial origin are the most frequent neoplasms of the lacrimal drainage system (LDS). A total of 539 cases are reported in the literature from 1960 to 2019. LDS carcinoma is a disease of the middle-aged and elderly population, with a median age at diagnosis of 57 years. Overall, there is a slight male predominance. Reported risk factors are chronic inflammation, LDS papilloma, and infection with oncogenic viruses. Symptoms of an LDS carcinoma resemble those of benign, inflammatory diseases, with epiphora from obstruction of the LDS as the most frequently encountered symptom. The median time from symptoms to diagnosis is 12 months and even longer for patients reporting epiphora as the only initial symptom. This diagnostic delay leads to a substantial fraction of patients with locally advanced tumors and lymph node spread at the time of diagnosis. Surgery with adjuvant radiotherapy is the treatment of choice for most patients; however, the extension and aggressiveness of the disease and the patient's general health and preferences determine the definite treatment. Five-year overall survival is reported to range from 61 to 87.6%. A large tumor size and positive lymph node status correlate with a decreased overall and disease-free survival.
由上皮组织起源的恶性肿瘤是泪液排出系统(LDS)最常见的肿瘤。1960 年至 2019 年期间,文献中报道了 539 例此类病例。LDS 癌主要发生于中老年人群,中位诊断年龄为 57 岁。总体上,男性略占优势。据报道的风险因素包括慢性炎症、LDS 乳头瘤和致癌病毒感染。LDS 癌的症状与良性炎症性疾病相似,以 LDS 阻塞引起的溢泪为最常见的症状。从出现症状到确诊的中位时间为 12 个月,对于仅以溢泪为首发症状的患者,这一时间甚至更长。这种诊断延迟导致相当一部分患者在诊断时已经存在局部晚期肿瘤和淋巴结转移。对于大多数患者来说,手术联合辅助放疗是治疗的首选方法;然而,疾病的范围和侵袭性、患者的整体健康状况和偏好决定了具体的治疗方法。报道的 5 年总生存率为 61%至 87.6%。肿瘤较大和淋巴结阳性与总生存率和无病生存率降低相关。